PMV Pharma
Feb 23, 2017
PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch
PMV Pharma Raises $74M, Aiming to Hit Cancer’s Hard Target- P53 PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The company raised a $74 million Series B round from Topspin Biotech Fun...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
